Eugene A. Bauer Sells 3,000 Shares of Dermira Inc (DERM) Stock

Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.07, for a total value of $81,210.00. Following the transaction, the insider now directly owns 5,802 shares of the company’s stock, valued at $157,060.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eugene A. Bauer also recently made the following trade(s):

  • On Monday, December 18th, Eugene A. Bauer sold 3,000 shares of Dermira stock. The shares were sold at an average price of $27.34, for a total value of $82,020.00.

Shares of Dermira Inc (DERM) opened at $27.35 on Friday. Dermira Inc has a 52-week low of $21.35 and a 52-week high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68. The stock has a market capitalization of $1,110.00, a P/E ratio of -4.39 and a beta of 0.80.

Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA raised its position in Dermira by 2,220.7% during the second quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 3,975 shares during the period. Quantbot Technologies LP raised its position in Dermira by 75.4% during the third quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares during the period. SG Americas Securities LLC raised its position in Dermira by 66.8% during the second quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 2,203 shares during the period. Legal & General Group Plc raised its position in Dermira by 40.9% during the second quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,803 shares during the period. Finally, Ardsley Advisory Partners purchased a new stake in Dermira during the second quarter valued at approximately $291,000. Institutional investors and hedge funds own 99.47% of the company’s stock.

A number of equities analysts recently commented on the company. Leerink Swann reissued an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $43.00 price target (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and set a $45.00 price target on shares of Dermira in a research note on Monday, November 6th. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, Guggenheim restated a “buy” rating and set a $30.00 price objective on shares of Dermira in a research report on Thursday, December 14th. Three investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $41.00.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/06/eugene-a-bauer-sells-3000-shares-of-dermira-inc-derm-stock.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

What are top analysts saying about Dermira? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit